The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer
Abstract
PURPOSE: A common late effect of doxorubicin therapy for childhood cancer is reduced left-ventricular (LV) wall thickness resulting in elevated LV afterload and depressed LV function. Many children are given angiotensin-converting enzyme inhibitors, which have been studied primarily in adults. We document the long-term effects of angiotensin-converting enzyme inhibitors in doxorubicin-treated survivors of childhood cancer. PATIENTS AND METHODS: In this retrospective study, we reviewed records of 18 children who had regular echocardiographic examinations during enalapril therapy (mean age at cancer diagnosis, 8 years; mean time between completion of doxorubicin therapy and start of enalapril, 7 years; median follow-up since the start of enalapril, 10 years). RESULTS: Over the first 6 years of enalapril therapy, there was progressive improvement toward normal values in LV dimension, afterload, fractional shortening, and mass, but all these parameters deteriorated between 6 and 10 years. LV wall thickness deteriorated throughout the study period, as did LV contractility and systolic blood pressure. Diastolic blood pressure fell slightly. By 6 years on enalapril, all six patients who had had congestive heart failure at the start of enalapril therapy had either died or undergone cardiac transplantation, compared with three of the 12 asymptomatic patients. CONCLUSION: In doxorubicin-treated long-term survivors of childhood cancer, enalapril-induced improvement in LV structure and function is transient. The primary defect, which is LV wall thinning, continues to deteriorate, and thus the short-term improvement was mostly related to lowered diastolic blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,229
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Self-citationLipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Self-citationMertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3163 · Cited by 798
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Epidemiology of anthracycline cardiotoxicity in children and adults.
Ma, G., & Se, L. (1998) · PubMed · Cited by 341
Cited by
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Anthracycline-Induced Cardiomyopathy
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,105
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
“Treatment is associated with improved cardiac event-free survival, and the clinical benefit appears greatest if the medication is started early (within 6 months) versus late (>1 year).(158,159) No specific trials have evaluated the efficacy of ARB or BB therapy alone in patients with anthracycline-induced reduced LVEF.”
BackgroundBozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000455 · Cited by 891
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.121 · Cited by 727
Self-citationPrevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Self-citationLipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Self-citationArmstrong, G. T., Kawashima, T., Leisenring, W., Stratton, K., Stovall, M., Hudson, M. M., Sklar, C. A., Robison, L. L., & Oeffinger, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1055 · Cited by 584
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Self-citationWouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Self-citationLipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Self-citationAnthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
Self-citationOeffinger, K. C., & Hudson, M. M. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.4.208 · Cited by 365
Trends and advances in cancer survivorship research: challenge and opportunity
AZIZ, N., & ROWLAND, J. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00024-9 · Cited by 330
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Self-citationSilber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.022 · Cited by 299
van Dalen, E. C., van der Pal, H. J. H., Kok, W. E. M., Caron, H. N., & Kremer, L. C. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.005 · Cited by 284
Metadata
- Authors
- Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C., Shaikh, S. L., Mone, S. M., Gelber, R. D., & Colan, S. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-12-01
- Volume
- 20
- Issue
- 23
- Pages
- 4517-4522
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2003943979
- Cited by
- 308
- References
- 18
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.